Abiopharma

Atkinson Charles 🟢 acquired 1.0K shares of PERRIGO Co plc (PRGO) at $23.20 Transaction Date: Sep 05, 2025 | Filing ID: 000137

Dilsaver Evelyn S 🟡 adjusted position in 11.8K shares (3 derivative) of HEALTHEQUITY, INC. (HQY) at $93.30 ($1.4M) Transaction Date: Sep 05, 2025 | Filing ID: 023962

New Form 144 - PTC THERAPEUTICS, INC. Filed: 2025-09-09 AccNo: 0001959173-25-005867 Size: 4 KB

New Form 8-K - Serina Therapeutics, Inc. Filed: 2025-09-09 AccNo: 0001708599-25-000108 Size: 252 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

New Form 144 - Arcutis Biotherapeutics, Inc. Filed: 2025-09-09 AccNo: 0002007317-25-001055 Size: 5 KB

New Form 144 - CORE MOLDING TECHNOLOGIES INC Filed: 2025-09-09 AccNo: 0001949846-25-000456 Size: 8 KB

New Form 6-K - GENMAB A/S Filed: 2025-09-09 AccNo: 0001434265-25-000074 Size: 225 KB

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

França concede acesso compassivo (AAC) reembolsável ao BOT/BAL da Agenus no câncer colorretal metastático MSS refratário

Francia otorga acceso compasivo (AAC) reembolsado para el tratamiento BOT/BAL de Agenus en el cáncer colorrectal metastásico refractario con MSS

La Francia concede laccesso compassionevole (AAC) rimborsato per BOT/BAL di Agenus nel tumore colorettale metastatico MSS

フランス、難治性MSS転移性大腸がんにおけるアジーナスのBOT/BALに償還付きコンパッショネートアクセス（AAC）を承認

法國核准Agenus的BOT/BAL用於難治性MSS轉移性大腸癌的同情用藥報銷(AAC)